I-Mab (NASDAQ:IMAB) said on Thursday that it has signed an agreement to acquire Bridge Health Biotech in a bid to gain upstream rights to CLDN18.2 parental antibody used in its experimental cancer ...

Yesterday, multiple media sources reported that AbbVie is stopping its phase 1 clinical trial of lemzoparlimab (“lemzo”) as part of a combination treatment for myelodysplastic syndromes, or MDS, and ...